Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Operating Leases (2022 - 2025)

Historic Operating Leases for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $41.2 million.

  • Century Therapeutics' Operating Leases fell 1898.62% to $41.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year decrease of 1898.62%. This contributed to the annual value of $49.0 million for FY2024, which is 493.38% up from last year.
  • As of Q3 2025, Century Therapeutics' Operating Leases stood at $41.2 million, which was down 1898.62% from $46.6 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Operating Leases ranged from a high of $52.7 million in Q2 2024 and a low of $14.4 million during Q1 2022
  • For the 4-year period, Century Therapeutics' Operating Leases averaged around $41.8 million, with its median value being $44.3 million (2024).
  • Per our database at Business Quant, Century Therapeutics' Operating Leases surged by 18529.45% in 2023 and then plummeted by 1898.62% in 2025.
  • Century Therapeutics' Operating Leases (Quarter) stood at $38.7 million in 2022, then rose by 20.57% to $46.7 million in 2023, then rose by 4.93% to $49.0 million in 2024, then fell by 15.88% to $41.2 million in 2025.
  • Its last three reported values are $41.2 million in Q3 2025, $46.6 million for Q2 2025, and $47.8 million during Q1 2025.